Metagenomi gets US regulator's green light to test hemophilia A editing drug in people

Metagenomi Therapeutics has secured US regulatory permission to begin testing MGX-001, a gene-editing treatment for hemophilia A designed to be given once, in patients. The company disclosed the Food and Drug Administration's decision on 10 November 2026, the same day it published third-quarter results.

The company plans to launch a combined Phase 1/2 study called INTEGR8 in the first half of 2027. It expects to report its first clinical readout in the second half of that year, so the earliest evidence on how the therapy performs in people is roughly a year away.

On the balance sheet, Metagenomi reported cash of $101.7 million and said this should finance operations into 2028. On those figures, the funding is guided to cover the start of the trial and the first data release; the facts provided do not say what later development would cost or how it would be paid for.

Some context: an investigational new drug clearance means the agency has reviewed the preclinical and manufacturing information filed and has not imposed a clinical hold, so human dosing can start. It says nothing about whether the treatment works and is not a marketing approval.

MGX-001 would join a hemophilia A field that already has established treatments, and it adds another in vivo editing candidate to the pipeline of the disease. The company has not yet given any details on pricing, reimbursement or commercial positioning.